Form 4: Apogee CMO Sells 10,900 Shares Under 10b5-1 Plan

Carl Dambkowski, Chief Medical Officer of Apogee Therapeutics, sold 10,900 shares of common stock for approximately $75 per share as part of a pre-arranged trading plan.

Summary

• Carl Dambkowski, Chief Medical Officer of Apogee Therapeutics, Inc. (APGE), reported a sale of common stock.
• The transaction involved the disposition of 10,900 shares of Apogee Therapeutics common stock.
• The shares were sold on December 4, 2025, at a weighted average price of $75 per share, with individual sales ranging from $75.00 to $75.01.
• The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024.
• Following this transaction, Mr. Dambkowski directly beneficially owns 271,108 shares of common stock.

Sentiment

Score: 5

Explanation: The sale of shares by the Chief Medical Officer, while a disposition, was executed under a pre-arranged Rule 10b5-1 trading plan, which typically indicates a planned financial event rather than a reaction to new, negative information, leading to a neutral sentiment.

Positives

• The sale was conducted under a Rule 10b5-1 trading plan, indicating it was pre-scheduled and not based on recent non-public information, which can mitigate negative investor perception.

Negatives

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived by investors as a lack of confidence in the company's near-term prospects, though this is mitigated by the pre-arranged nature.

Future Outlook

NA

Industry Context

This filing is a standard insider transaction report for a biotechnology company. Insider sales are common for executives for personal financial planning, diversification, or liquidity, especially when executed under a 10b5-1 plan, which is a common practice across industries to avoid accusations of trading on inside information.

Stakeholder Impact

• Shareholders may observe the insider sale and consider its implications for management's confidence, although the 10b5-1 plan mitigates immediate concerns.

Key Dates

Recommendation

A single insider sale, even by a high-ranking officer, especially when conducted under a pre-arranged 10b5-1 plan, is generally not a strong enough signal on its own to warrant a 'buy' or 'sell' recommendation. It's often part of personal financial planning. Investors should consider this transaction in the broader context of the company's performance, pipeline, and overall market conditions.

Keywords

Apogee Therapeutics, APGE, Carl Dambkowski, Chief Medical Officer, Insider Sale, Form 4, 10b5-1 Plan, Stock Transaction, Beneficial Ownership